|
JENEX / SHOPPERS DRUG MART TO LAUNCH interceptCS
COLD SORE PREVENTION PRODUCT TO BE LAUNCHED WITH
SHOPPERS DRUG MART
FOR IMMEDIATE RELEASE
November 5, 2004
Burlington, Ontario
THE JENEX CORPORATION (“Jenex” or the “Corporation”) (TSX Venture Exchange – JEN), Michael Jenkins, President and CEO of Jenex reports Shoppers Drug Mart has agreed to be our exclusive partner for the launch of interceptCS (the first product proven and approved to prevent cold sores). interceptCS will be distributed exclusively for a predetermined period of time at Shoppers Drug Mart and Pharmaprix stores across Canada.
Mr. Jenkins states,” we are pleased to have Shoppers Drug Mart as our exclusive partner for the launch of interceptCS . The interceptCS medical device has been clinically proven safe and effective and will be available over-the-counter, allowing easy access to the product without a prescription. This is a significant milestone in the further commercialization of our patented technology.”
Jenex is scheduled to launch interceptCS with Shoppers Drug Mart in the first quarter of 2005. In Canada there are between 5 and 10 million recurrent cold sore sufferers. Being the only product on the market proven to prevent cold sores, interceptCS expects to capture a significant share of this large and underdeveloped category.
Shoppers Drug Mart is one of the most recognized and trusted names in Canadian retailing. The Company is the licensor of full-service retail drug stores operating under the name Shoppers Drug Mart (Pharmaprix in Quebec). With 878 Shoppers Drug Mart and Pharmaprix stores operating in prime locations in every province and two territories, the Company is one of the most convenient retailers in Canada. The Company also owns and operates 48 Shoppers Home Health Care stores, making it the largest Canadian retailer of home health care products and services.
About The Jenex Corporation
Headquartered in Burlington, Ontario, the Corporation owns a patented Thermal Therapy technology. Patents in the United States, Canada, Australia, and Europe protect the technology. The first device developed from this technology is the Therapik® product, for insect stings and bites. The second device, interceptCS is the first product proven and approved to prevent cold sores. Jenex has been approved to market interceptCS in Canada with its approved claim, “For prevention and relief of the symptoms of herpes labialis (cold sores), such as blistering, lesions, inflammation, and discomfort. Also helps alleviate the embarrassment that is typically associated with herpes labialis (cold sore) outbreaks”. The Corporation is preparing for the launch of interceptCS in the Canadian market in the first quarter 2005. Regulatory approvals are being pursued for USA, Europe and Australia. It is estimated that between 45 and 90 million people in North America suffer from recurrent cold sores. More information about the Corporation can be found at: www.jenexcorp.com .
Direct Inquiries:
Michael Jenkins,
The Jenex Corporation
E-Mail: jenex@jenexcorp.com
Tel: (905) 632-3830 Fax: (905) 632-3774
The TSX Venture Exchange has not reviewed and does not accept responsibility for the accuracy or the contents of this press release. Certain information included in this press release is forward-looking and is subject to important risks and uncertainties. The results or events predicted in these statements may differ materially from actual results or events.
|
